123 related articles for article (PubMed ID: 27100979)
21. Comparative study on the level of B lymphocyte stimulator (BlyS) and frequency of lymphocytes between sero-negative and sero-positive rheumatoid arthritis patients.
Geng Y; Zhang ZL
Int J Rheum Dis; 2012 Oct; 15(5):478-85. PubMed ID: 23083038
[TBL] [Abstract][Full Text] [Related]
22. Baseline predictors of systemic lupus erythematosus flares: data from the combined placebo groups in the phase III belimumab trials.
Petri MA; van Vollenhoven RF; Buyon J; Levy RA; Navarra SV; Cervera R; Zhong ZJ; Freimuth WW;
Arthritis Rheum; 2013 Aug; 65(8):2143-53. PubMed ID: 23754628
[TBL] [Abstract][Full Text] [Related]
23. Targeting B lymphocyte stimulator in systemic lupus erythematosus and other autoimmune rheumatic disorders.
Stohl W
Expert Opin Ther Targets; 2004 Jun; 8(3):177-89. PubMed ID: 15161425
[TBL] [Abstract][Full Text] [Related]
24. Inverse association between circulating APRIL levels and serological and clinical disease activity in patients with systemic lupus erythematosus.
Stohl W; Metyas S; Tan SM; Cheema GS; Oamar B; Roschke V; Wu Y; Baker KP; Hilbert DM
Ann Rheum Dis; 2004 Sep; 63(9):1096-103. PubMed ID: 15308519
[TBL] [Abstract][Full Text] [Related]
25. The reduction of serum B-lymphocyte activating factor levels following quinacrine add-on therapy in systemic lupus erythematosus.
Toubi E; Kessel A; Rosner I; Rozenbaum M; Paran D; Shoenfeld Y
Scand J Immunol; 2006 Apr; 63(4):299-303. PubMed ID: 16623930
[TBL] [Abstract][Full Text] [Related]
26. Elevated serum BAFF levels are associated with rising anti-double-stranded DNA antibody levels and disease flare following B cell depletion therapy in systemic lupus erythematosus.
Carter LM; Isenberg DA; Ehrenstein MR
Arthritis Rheum; 2013 Oct; 65(10):2672-9. PubMed ID: 23839909
[TBL] [Abstract][Full Text] [Related]
27. 17-β-estradiol affects BLyS serum levels and the nephritogenic autoantibody network accelerating glomerulonephritis in NZB/WF1 mice.
Bassi N; Luisetto R; Ghirardello A; Gatto M; Valente M; Della Barbera M; Nalotto L; Punzi L; Doria A
Lupus; 2015 Apr; 24(4-5):382-91. PubMed ID: 25801881
[TBL] [Abstract][Full Text] [Related]
28. Serum BLyS/BAFF predicts the outcome of acute hepatitis C virus infection.
Tarantino G; Marco VD; Petta S; Almasio PL; Barbaria F; Licata A; Bosco GL; Tripodo C; Stefano RD; Craxì A
J Viral Hepat; 2009 Jun; 16(6):397-405. PubMed ID: 19200135
[TBL] [Abstract][Full Text] [Related]
29. Hepatitis C virus-associated B-cell proliferation--the role of serum B lymphocyte stimulator (BLyS/BAFF).
Sène D; Limal N; Ghillani-Dalbin P; Saadoun D; Piette JC; Cacoub P
Rheumatology (Oxford); 2007 Jan; 46(1):65-9. PubMed ID: 16782735
[TBL] [Abstract][Full Text] [Related]
30. Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus.
Zhang J; Roschke V; Baker KP; Wang Z; Alarcón GS; Fessler BJ; Bastian H; Kimberly RP; Zhou T
J Immunol; 2001 Jan; 166(1):6-10. PubMed ID: 11123269
[TBL] [Abstract][Full Text] [Related]
31. Analysis on the association of human BLYS (BAFF, TNFSF13B) polymorphisms with systemic lupus erythematosus and rheumatoid arthritis.
Kawasaki A; Tsuchiya N; Fukazawa T; Hashimoto H; Tokunaga K
Genes Immun; 2002 Nov; 3(7):424-9. PubMed ID: 12424625
[TBL] [Abstract][Full Text] [Related]
32. Association of serum B cell activating factor from the tumour necrosis factor family (BAFF) and a proliferation-inducing ligand (APRIL) with central nervous system and renal disease in systemic lupus erythematosus.
Vincent FB; Northcott M; Hoi A; Mackay F; Morand EF
Lupus; 2013 Aug; 22(9):873-84. PubMed ID: 23846230
[TBL] [Abstract][Full Text] [Related]
33. BLyS and APRIL form biologically active heterotrimers that are expressed in patients with systemic immune-based rheumatic diseases.
Roschke V; Sosnovtseva S; Ward CD; Hong JS; Smith R; Albert V; Stohl W; Baker KP; Ullrich S; Nardelli B; Hilbert DM; Migone TS
J Immunol; 2002 Oct; 169(8):4314-21. PubMed ID: 12370363
[TBL] [Abstract][Full Text] [Related]
34. High expression of B lymphocyte stimulator in lesional keratinocytes of patients with cutaneous lupus erythematosus.
Wenzel J; Landmann A; Vorwerk G; Kuhn A
Exp Dermatol; 2018 Jan; 27(1):95-97. PubMed ID: 28833566
[TBL] [Abstract][Full Text] [Related]
35. The role of B lymphocyte stimulator in B cell biology: implications for the treatment of lupus.
Scholz JL; Oropallo MA; Sindhava V; Goenka R; Cancro MP
Lupus; 2013 Apr; 22(4):350-60. PubMed ID: 23553778
[TBL] [Abstract][Full Text] [Related]
36. APRIL levels strongly correlate with IL-17 in systemic lupus erythematosus.
Eilertsen GØ; Nossent JC
Lupus; 2014 Nov; 23(13):1383-91. PubMed ID: 25057039
[TBL] [Abstract][Full Text] [Related]
37. Targeting the BLyS-APRIL signaling pathway in SLE.
La Cava A
Clin Immunol; 2013 Sep; 148(3):322-7. PubMed ID: 23269199
[TBL] [Abstract][Full Text] [Related]
38. BlySfulness does not equal blissfulness in systemic lupus erythematosus: a therapeutic role for BLyS antagonists.
Stohl W
Curr Dir Autoimmun; 2005; 8():289-304. PubMed ID: 15564726
[TBL] [Abstract][Full Text] [Related]
39. Differential effects on BAFF and APRIL levels in rituximab-treated patients with systemic lupus erythematosus and rheumatoid arthritis.
Vallerskog T; Heimbürger M; Gunnarsson I; Zhou W; Wahren-Herlenius M; Trollmo C; Malmström V
Arthritis Res Ther; 2006; 8(6):R167. PubMed ID: 17092341
[TBL] [Abstract][Full Text] [Related]
40. Therapeutic targeting of B lymphocyte stimulator (BLyS) in the rheumatic diseases.
Stohl W
Endocr Metab Immune Disord Drug Targets; 2006 Dec; 6(4):351-8. PubMed ID: 17214581
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
